Johnson & Johnson has reported first-in-human Phase 1 results for a dual-bispecific immunotherapy regimen combining pasritamig with JNJ-9401 in metastatic castration-resistant prostate cancer, with 11 of 15 patients treated at the recommended regimen achieving a prostate-specific antigen reduction of at least 50%. Seven of the 15 patients achieved PSA reductions of at least 90%, while four reached undetectable PSA levels, providing an early signal that simultaneously targeting KLK2 and PSMA could intensify T-cell activity against heavily pretreated prostate cancer.
The result is clinically intriguing because prostate cancer has historically proved difficult to treat with immunotherapy, particularly compared with tumours such as melanoma or lung cancer. However, the 73% figure should not be interpreted as a 73% objective tumour response rate, nor does the Phase 1 study establish improved progression-free or overall survival. PSA decline is an important marker of antitumour activity in advanced prostate cancer, but the significance of the combination will ultimately depend on whether these biochemical responses translate into durable radiographic disease control and longer survival in randomized Phase 3 testing.
Johnson & Johnson is already taking that question into the KLK2-comPAS Phase 3 programme, which evaluates pasritamig alone and in combination with JNJ-9401 in metastatic castration-resistant prostate cancer. The strategic bet is that adding a second, complementary T-cell signal can deepen the activity previously seen with pasritamig alone without producing the severe cytokine-release and neurological toxicities that have complicated development of some T-cell-engaging therapies.
Why does combining KLK2 and PSMA targeting create a different prostate cancer immunotherapy strategy?
Pasritamig is a bispecific T-cell engager that targets human kallikrein 2, or KLK2, on prostate cancer cells while simultaneously binding CD3 on T cells. KLK2 is closely associated with prostate tissue and androgen-receptor signalling, giving Johnson & Johnson a tumour-associated target that can potentially direct immune cells towards prostate cancer while limiting exposure in most normal tissues.
JNJ-9401 adds a second biological component. The investigational bispecific targets prostate-specific membrane antigen, or PSMA, on cancer cells and CD28 on T cells, providing a costimulatory signal intended to strengthen and sustain T-cell activation initiated by pasritamig. Rather than using two antibodies that independently trigger the same immune mechanism, Johnson & Johnson is attempting to reproduce the two signals normally required for effective T-cell activation.
This architecture potentially addresses one of the central challenges of prostate cancer immunotherapy. Prostate tumours often have relatively limited immune-cell infiltration and have generally responded poorly to conventional checkpoint inhibitors, making it difficult to release an existing antitumour immune response when relatively little effective T-cell activity exists in the tumour to begin with.
The pasritamig-JNJ-9401 approach instead attempts to actively redirect and stimulate T cells using two prostate-associated antigens. The biological rationale is credible, but its sophistication does not establish clinical superiority. Phase 3 testing must show whether the additional costimulatory signal meaningfully improves patient outcomes compared with pasritamig alone or other available late-line treatments.
How meaningful is the 73% PSA50 result when only 15 patients received the recommended regimen?
The ongoing Phase 1 trial enrolled 144 patients across dose-escalation and optimisation cohorts, but the most striking efficacy numbers come from only 15 patients receiving the regimen Johnson & Johnson selected for further development. Those patients were heavily pretreated, having received a median of four previous systemic treatment lines, with individual exposure ranging from two to six lines.
All had previously received an androgen-receptor pathway inhibitor. Approximately two-thirds had received taxane chemotherapy, and about two-thirds had also received radioligand therapy, placing the group deep into the metastatic castration-resistant treatment pathway where durable disease control becomes progressively harder to achieve.
At the recommended regimen, 73% achieved PSA50 and 47% achieved PSA90. Four patients, representing roughly 27% of the cohort, reached undetectable PSA levels. All seven patients achieving PSA90 remained on therapy for more than six months without disease progression at the June 15, 2026 data cutoff, adding an early durability dimension to the biochemical response.
The sample size substantially limits precision. Eleven responders can generate a compelling percentage in a 15-patient cohort, but only a few additional non-responders in a larger population would materially change the response estimate. The data therefore support advancement rather than establish the treatment effect that clinicians should expect in routine care.
Why should PSA reduction not be confused with a confirmed survival benefit?
PSA is deeply embedded in prostate cancer monitoring because changes can provide useful information about biological activity and treatment response. A decline of at least 50% is commonly used as a measure of activity in clinical development, while deeper declines such as PSA90 can strengthen evidence that a treatment is affecting the cancer.
Yet PSA remains a biomarker rather than an endpoint equivalent to overall survival. A drug can produce substantial PSA changes without necessarily extending life, and the relationship between biochemical response and clinically meaningful outcomes varies according to treatment mechanism and disease setting.
The current Johnson & Johnson dataset therefore cannot establish that 73% of patients experienced a clinically meaningful response in the broader sense. Radiographic progression-free survival, objective tumour responses among patients with measurable disease, symptoms, skeletal events and overall survival provide different and complementary information.
This distinction becomes particularly important because the Phase 3 KLK2-comPAS programme uses overall survival as a central test of the strategy. If the deeper PSA reductions produced by adding JNJ-9401 ultimately translate into longer survival, the Phase 1 result will have identified an important early pharmacodynamic signal. If survival does not improve, the striking PSA percentages will prove considerably less consequential.
What does earlier pasritamig monotherapy evidence tell us about the contribution of JNJ-9401?
Pasritamig already had clinical evidence before JNJ-9401 was added. A peer-reviewed Phase 1 study involving 174 patients with metastatic castration-resistant prostate cancer established a recommended intravenous dose of 300 mg every six weeks following step-up dosing.
Among 33 patients in the pasritamig monotherapy recommended-dose efficacy population, 42.4% achieved PSA50. Median radiographic progression-free survival was 7.85 months, although the confidence interval was wide because of the small population and early-phase design.
The 73% PSA50 rate seen with pasritamig plus JNJ-9401 therefore appears numerically higher than the 42.4% reported with pasritamig monotherapy at its recommended dose. That difference cannot establish that JNJ-9401 adds benefit because the results come from different cohorts, with potentially different patient characteristics and follow-up, rather than a randomized head-to-head comparison.
Johnson & Johnson has designed Phase 3 development to answer precisely this problem. Evaluating pasritamig with and without the PSMA-directed costimulatory antibody within the same controlled programme should provide a much cleaner assessment of whether adding JNJ-9401 produces enough incremental efficacy to justify a two-bispecific regimen.
Does the early safety profile solve one of the biggest problems with T-cell engagers?
T-cell-engaging therapies can generate cytokine release syndrome when activated immune cells release inflammatory signalling molecules. More severe immune toxicity can require hospital observation or intervention, creating a significant implementation challenge for therapies intended for large solid-tumour populations.
At the recommended pasritamig plus JNJ-9401 regimen, 46.7% of the 15 patients experienced treatment-related adverse events, but Johnson & Johnson reported no Grade 3 or higher treatment-related events, dose-limiting toxicities, treatment-related discontinuations or treatment-related deaths. Cytokine release syndrome occurred in three patients, or 20%, with all events classified as Grade 1 and presenting as temporary fever.
No immune effector cell-associated neurotoxicity syndrome was reported in the recommended-dose cohort. Two patients experienced reversible Grade 1 increases in liver enzymes, while none of the three patients with cytokine release syndrome required treatment with tocilizumab.
The broader 144-patient dataset shows why the selected regimen matters. Across all doses, 12.5% experienced Grade 3 or higher treatment-related adverse events, and immune-mediated hepatitis was observed at higher JNJ-9401 exposures or with more frequent dosing. Those events were reported as reversible with steroids, but they demonstrate that the tolerability seen at 200 mg every six weeks cannot simply be extrapolated to greater exposure.
Could every-six-week dosing make dual bispecific therapy practical outside specialist inpatient centres?
The recommended regimen uses JNJ-9401 200 mg subcutaneously every six weeks with pasritamig 300 mg intravenously every six weeks following two initial weekly step-up doses of pasritamig. Johnson & Johnson is positioning the schedule for outpatient administration, which could become commercially important if Phase 3 testing confirms an acceptable safety profile.
Frequency matters because advanced prostate cancer increasingly involves prolonged treatment across several lines, and therapies requiring intensive inpatient monitoring can create substantial burdens for patients and health systems. A six-week maintenance interval could differentiate the regimen from T-cell therapies that demand more frequent administration or prolonged observation.
However, the combination still involves two separate biologics, different routes of administration and initial step-up dosing. Manufacturing costs, infusion infrastructure, reimbursement and specialist monitoring will therefore remain relevant even if severe cytokine release syndrome remains uncommon.
Commercial viability will ultimately depend on the balance between efficacy and complexity. A treatment delivering major survival improvement could justify a relatively involved delivery model, while modest incremental efficacy would face tougher comparisons against established oral drugs, chemotherapy, radioligand therapy and other emerging prostate cancer treatments.
Why is Phase 3 now far more important than another impressive Phase 1 percentage?
Johnson & Johnson has already moved the strategy into the KLK2-comPAS Phase 3 study in late-line metastatic castration-resistant prostate cancer. The trial is designed to evaluate pasritamig with or without JNJ-9401 against a control strategy, with overall survival providing a direct clinical test that the current PSA data cannot answer.
Pasritamig is also being evaluated with docetaxel in the Phase 3 KLK2-PASenger programme in first-line metastatic castration-resistant disease. Together, the studies show that Johnson & Johnson sees KLK2-directed T-cell engagement as a potential platform within advanced prostate cancer rather than a single late-line experiment.
The company already has an unusually broad prostate cancer franchise spanning androgen-receptor therapy, PARP inhibition, radioligand therapy and experimental immunotherapies. A successful bispecific programme could add another mechanism and potentially provide treatment options after resistance to existing modalities develops.
The challenge is that advanced prostate cancer treatment is evolving rapidly. Radioligand therapy targeting PSMA, new androgen-receptor strategies, antibody-drug conjugates and other bispecific programmes are all competing for increasingly specific positions in the treatment sequence. A future pasritamig regimen therefore needs more than biological novelty; it needs a clinically meaningful advantage.
What does Johnson & Johnson’s stock sentiment suggest about the importance of the programme?
Johnson & Johnson shares closed at $276.22 on November 6, up 1.43% for the session and roughly 2% over the preceding week. The stock was trading only about 2% below its 52-week high of approximately $282 and had gained roughly one-third during 2026, giving the company a market capitalisation of about $665 billion.
At that scale, a 15-patient Phase 1 prostate cancer dataset is unlikely to determine near-term valuation by itself. Johnson & Johnson’s share performance reflects a diversified pharmaceutical and medical technology business with multiple major commercial franchises, litigation exposure and a broad late-stage pipeline.
The pasritamig programme is better viewed as a long-duration oncology pipeline signal. Positive Phase 3 survival data could eventually add another substantial franchise to Johnson & Johnson’s prostate cancer portfolio, but early PSA reductions have little immediate earnings relevance before the treatment progresses through confirmatory development and regulatory review.
Investor attention should therefore focus less on the 73% headline and more on whether Johnson & Johnson has identified a combination capable of improving outcomes without reproducing the toxicity and logistical limitations that have constrained other T-cell-directed approaches in solid tumours.
Can dual T-cell signalling finally make immunotherapy relevant in advanced prostate cancer?
The Phase 1 data provide one of the more interesting signals yet for a deliberately engineered T-cell immunotherapy strategy in metastatic castration-resistant prostate cancer. Achieving PSA50 in 11 of 15 heavily pretreated patients, PSA90 in seven and undetectable PSA in four suggests biologically meaningful activity at the selected regimen, particularly when pasritamig alone had already demonstrated proof of concept for KLK2 targeting.
The evidence is nevertheless at an early stage. The dataset is small, non-randomized and based heavily on PSA changes rather than a demonstrated survival advantage, while meaningful questions remain around radiographic outcomes, durability and how much additional benefit is actually contributed by JNJ-9401.
What makes the programme more consequential than a typical Phase 1 readout is that Johnson & Johnson is not waiting for another small expansion cohort to define its ambitions. Phase 3 testing is already under way, with a design capable of determining whether adding PSMA-directed CD28 costimulation to KLK2-directed T-cell engagement produces a survival advantage.
The 73% PSA50 rate has therefore earned the combination a serious test rather than a clinical conclusion. If KLK2-comPAS shows that the biochemical responses translate into longer survival with manageable toxicity and practical outpatient dosing, Johnson & Johnson may have found a way to make a traditionally immunologically resistant tumour meaningfully vulnerable to T-cell therapy.
